The use of group sequential, information-based sample size re-estimation in the design of the PRIMO study of chronic kidney disease

Clinical Trials

Volumn 8, Issue 2, 2011, Pages 165-174

  Pritchett, Yili ^a   Jemiai, Yannis ^b   Chang, Yuchiao ^c   Bhan, Ishir ^c   Agarwal, Rajiv ^d   Zoccali, Carmine ^e   Wanner, Christoph ^f   Lloyd Jones, Donald ^g   Cannata Andía, Jorge B ^h   Thompson, Taylor ^c   Appelbaum, Evan ⁱ   Audhya, Paul ^a   Andress, Dennis ^a   Zhang, Wuyan ^a   Solomon, Scott ⁱ   Manning, Warren J ⁱ   Thadhani, Ravi ^c  

^a ABBOTT LABORATORIES   (United States)

^b Cytel Incorporated   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e Nephrology Dialysis and Transplantation Unit   (Italy)

^f UNIVERSITY OF WÜRZBURG   (Germany)

^g NORTHWESTERN UNIVERSITY   (United States)

^h HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

ⁱ HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PARICALCITOL; PLACEBO;

CARDIOVASCULAR MAGNETIC RESONANCE; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HUMAN; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; STUDY DESIGN;

BONE DENSITY CONSERVATION AGENTS; DATA INTERPRETATION, STATISTICAL; ERGOCALCIFEROLS; FEMALE; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; KIDNEY FAILURE, CHRONIC; MALE; RECEPTORS, CALCITRIOL; SAMPLE SIZE; TIME FACTORS; TREATMENT OUTCOME;

EID: 79959252941     PISSN: 17407745     EISSN: 17407753     Source Type: Journal    
DOI: 10.1177/1740774511399128     Document Type: Review

References (49)

1. Coresh J, Selvin E, Stevens LA, et al. Prevalence of chronic kidney disease in the United States. Jama 2007; 298: 2038-47. (Pubitemid 350074801)
2. Department of Health and Human Services. Disparities in premature deaths from heart disease-50 states and the district of Columbia, 2001. MMWR Morb Mortal Wkly Rep 2004; 53: 121-25.
3. Levy D, Garrison RJ, Savage DD, et al. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 1990; 322: 1561-66. (Pubitemid 20176696)
4. Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 1992; 327: 669-77.
5. Devereux RB, Wachtell K, Gerdts E, et al. Prognostic significance of left ventricular mass change during treatment of hypertension. Jama 2004; 292: 2350-56. (Pubitemid 39491919)
6. Stewart GA, Gansevoort RT, Mark PB, et al. Electrocardiographic abnormalities and uremic cardiomyopathy. Kidney Int 2005; 67: 217-26. (Pubitemid 40019243)
7. Verma A, Anavekar NS, Meris A, et al. The relationship between renal function and cardiac structure, function, and prognosis after myocardial infarction: the VALIANT Echo Study. J Am Coll Cardiol 2007; 50: 1238-45. (Pubitemid 47405128)
8. Teng M, Wolf M, Lowrie E, et al. Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy. N Engl J Med 2003; 349: 446-56. (Pubitemid 36910023)
9. Teng M, Wolf M, Ofsthun MN, et al. Activated injectable vitamin D and hemodialysis survival: a historical cohort study. J Am Soc Nephrol 2005; 16: 1115-25. (Pubitemid 41710323)
10. Kalantar-Zadeh K, Kuwae N, Regidor DL, et al. Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney Int 2006; 70: 771-80. (Pubitemid 44215354)
11. Shoben AB, Rudser KD, de Boer IH, et al. Association of oral calcitriol with improved survival in nondialyzed CKD. J Am Soc Nephrol 2008; 19: 1613-19.
12. Kovesdy CP, Ahmadzadeh S, Anderson JE, Kalantar-Zadeh K. Association of activated vitamin D treatment and mortality in chronic kidney disease. Arch Intern Med 2008; 168: 397-403. (Pubitemid 351350586)
13. Naves-Diaz M, Alvarez-Hernandez D, Passlick-Deetjen J, et al. Oral active vitamin D is associated with improved survival in hemodialysis patients. Kidney Int 2008; 74: 1070-78.
14. Bodyak N, Ayus JC, Achinger S, et al. Activated vitamin D attenuates left ventricular abnormalities induced by dietary sodium in Dahl salt-sensitive animals. P Natl Acad Sci USA 2007; 104: 16810-15. (Pubitemid 350210947)
15. Thadhani R. Targeted ablation of the vitamin D 1alpha-hydroxylase gene: getting to the heart of the matter. Kidney Int 2008; 74: 141-43. (Pubitemid 351915094)
16. Weishaar RE, Simpson RU. Vitamin D3 and cardiovascular function in rats. J Clin Invest 1987; 79: 1706-12.
17. Simpson RU, Hershey SH, Nibbelink KA. Characterization of heart size and blood pressure in the vitamin D receptor knockout mouse. J Steroid Biochem Mol Biol 2007; 103: 521-24. (Pubitemid 46420533)
18. Xiang W, Kong J, Chen S, et al. Cardiac hypertrophy in vitamin D receptor knockout mice: role of the systemic and cardiac renin-angiotensin systems. Am J Physiol Endocrinol Metab 2005; 288: E125-32.
19. Wu J, Garami M, Cheng T, Gardner DG. 1,25(OH)2 vitamin D3, and retinoic acid antagonize endothelin-stimulated hypertrophy of neonatal rat cardiac myocytes. J Clin Invest 1996; 97: 1577-88. (Pubitemid 26105467)
20. Thadhani R, Appelbaum E, Chang Y, et al. Vitamin D receptor activation and left ventricular hypertrophy in advanced kidney disease. Am J Nephrol 2011; 33: 139-49.
21. Stewart GA, Foster J, Cowan M, et al. Echocardiography overestimates left ventricular mass in hemodialysis patients relative to magnetic resonance imaging. Kidney Int 1999; 56: 2248-53. (Pubitemid 30004755)
22. Salton CJ, Chuang ML, O'Donnell CJ, et al. Gender differences and normal left ventricular anatomy in an adult population free of hypertension. A cardiovascular magnetic resonance study of the Framingham Heart Study Offspring cohort. J Am Coll Cardiol 2002; 39: 1055-60. (Pubitemid 34234130)
23. Bellenger NG, Davies LC, Francis JM, et al. Reduction in sample size for studies of remodeling in heart failure by the use of cardiovascular magnetic resonance. J Cardiovasc Magn Reson 2000; 2: 271-78. (Pubitemid 32048395)
24. Bottini PB, Carr AA, Prisant LM, et al. Magnetic resonance imaging compared to echocardiography to assess left ventricular mass in the hypertensive patient. Am J Hypertens 1995; 8: 221-28.
25. Culleton BF, Walsh M, Klarenbach SW, et al. Effect of frequent nocturnal hemodialysis vs conventional hemodialysis on left ventricular mass and quality of life: a randomized controlled trial. Jama 2007; 298: 1291-99. (Pubitemid 47443343)
26. Chan CT, Floras JS, Miller JA, et al. Regression of left ventricular hypertrophy after conversion to nocturnal hemodialysis. Kidney Int 2002; 61: 2235-39. (Pubitemid 34539341)
27. Bauer P, Kohne K. Evaluation of experiments with adaptive interim analyses. Biometrics 1994; 50: 1029-41.
28. Lehmacher W, Wassmer G. Adaptive sample size calculations in group sequential trials. Biometrics 1999; 55: 1286-90.
29. Muller HH, Schafer H. Adaptive group sequential designs for clinical trials: combining the advantages of adaptive and of classical group sequential approaches. Biometrics 2001; 57: 886-91. (Pubitemid 32801186)
30. Chi L, Hung HM, Wang SJ. Modification of sample size in group sequential clinical trials. Biometrics 1999; 55: 853-57. (Pubitemid 29427088)
31. Bornkamp B, Bretz F, Dmitrienko A, et al. Innovative approaches for designing and analyzing adaptive dose-ranging trials. J Biopharm Stat 2007; 17: 965-95. (Pubitemid 350135825)
32. Krams M, Lees KR, Hacke W, et al. Acute Stroke Therapy by Inhibition of Neutrophils (ASTIN): an adaptive dose-response study of UK-279,276 in acute ischemic stroke. Stroke 2003; 34: 2543-48. (Pubitemid 37392736)
33. Muss HB, Berry DA, Cirrincione CT, et al. Adjuvant chemotherapy in older women with early-stage breast cancer. N Engl J Med 2009; 360: 2055-65.
34. Mehta CR, Patel NR. Adaptive, group sequential and decision theoretic approaches to sample size determination. Stat Med 2006; 25: 3250-69; discussion 3297-301, 3302-04, 3313-14, 3326-47.
35. Ritz E, Laville M, Bilous RW, et al. Target level for hemoglobin correction in patients with diabetes and CKD: primary results of the Anemia Correction in Diabetes (ACORD) Study. Am J Kidney Dis 2007; 49: 194-207. (Pubitemid 46178405)
36. Levin A, Djurdjev O, Thompson C, et al. Canadian randomized trial of hemoglobin maintenance to prevent or delay left ventricular mass growth in patients with CKD. Am J Kidney Dis 2005; 46: 799-811. (Pubitemid 41505453)
37. Roger SD, McMahon LP, Clarkson A, et al. Effects of early and late intervention with epoetin alpha on left ventricular mass among patients with chronic kidney disease (stage 3 or 4): results of a randomized clinical trial. J Am Soc Nephrol 2004; 15: 148-56. (Pubitemid 38020706)
38. Parfrey PS, Foley RN, Wittreich BH, et al. Double-blind comparison of full and partial anemia correction in incident hemodialysis patients without symptomatic heart disease. J Am Soc Nephrol 2005; 16: 2180-89. (Pubitemid 41716451)
39. Pitt B, Reichek N, Willenbrock R, et al. Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4 E-left ventricular hypertrophy study. Circulation 2003; 108: 1831-38. (Pubitemid 37296092)
40. Solomon SD, Appelbaum E, Manning WJ, et al. Effect of the direct Renin inhibitor aliskiren, the Angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy. Circulation 2009; 119: 530-37.
41. Zoccali C, Benedetto FA, Mallamaci F, et al. Prognostic impact of the indexation of left ventricular mass in patients undergoing dialysis. J Am Soc Nephrol 2001; 12: 2768-74. (Pubitemid 33115425)
42. Mehta C, Tsiatis AA. Flexible sample size consideration using information-based interim monitoring. Drug Infor J 2001; 35: 1095-112. (Pubitemid 34563404)
43. Gould AL, Shih WJ. Sample size re-estimation without unblinding for normally distributed outcomes with unknown variance. Com Stat Theory Meth 1992; 21: 2833-53.
44. Pocock SJ. Group sequential methods in the design and analysis of clinical trials. Biometrika 1977; 64: 191-99. (Pubitemid 8145484)
45. O'Brien PC, Fleming TR. A multiple testing procedure for clinical trials. Biometrics 1979; 35: 549-56. (Pubitemid 10242750)
46. Lan KKG, De Mets DL. Discrete sequential boundaries for clinical trials. Biometrika 1983; 70: 659-63.
47. Hwang IK, Shih WJ, De Cani JS. Group sequential designs using a family of type I error probability spending functions. Stat Med 1990; 9: 1439-45.
48. Proschan MA, Liu Q, Hunsberger S. Practical midcourse sample size modification in clinical trials. Control Clin Trials 2003; 24: 4-15. (Pubitemid 36135942)
49. Mehta C, Gao P, Bhatt DL, et al. Optimizing trial design: sequential, adaptive, and enrichment strategies. Circulation 2009; 119: 597-605.